Medication-Related Risk Assessment in Implant Dentistry: MRONJ, Bleeding and Healing

PERI-EDU University Education

Medication-related risk cannot be determined from a drug name alone. Implant planning should consider the therapeutic indication, dose, route, schedule, duration, current disease status and the biological burden of the proposed procedure.

Medication history as a clinical risk map

Medicines can alter bone turnover, haemostasis, immune response, glucose control, vascular function and recovery from surgical stress. The same medicine may carry different implications when used for osteoporosis, metastatic cancer or another systemic condition.

Domain	Information to record	Decision supported
Exact exposure	Generic name, dose, route, frequency, start date, last dose and planned duration.	Prevents classification by a vague label such as bone medicine or blood thinner.
Indication	Osteoporosis, malignancy, atrial fibrillation, thrombosis, transplantation, inflammatory disease or psychiatric treatment.	Shows the harm that interruption or delay could cause.
Current stability	Recent hospitalization, infection, flare, cytopenia, bleeding, thrombosis or organ decompensation.	Separates stable long-term treatment from an unstable medical course.
Procedure burden	Osteotomy, augmentation, number of sites, anticipated bleeding and healing demand.	Links systemic risk with the actual intervention.
Local condition	Periodontal or endodontic infection, hygiene, mucosal trauma and prosthetic access.	Identifies modifiable oral drivers of complication.

Rigid lists of absolute and relative contraindications can hide important context. A more useful decision is whether to proceed, modify, defer or refer.

Antiresorptive therapy and MRONJ

Bisphosphonates suppress osteoclast-mediated resorption and remain in bone for prolonged periods. Denosumab inhibits RANKL and has a reversible pharmacological effect, but unplanned discontinuation can produce rebound bone turnover and vertebral fractures. Antiresorptive schedules used for malignant disease generally create greater MRONJ risk than osteoporosis regimens.

AAOMS defines medication-related osteonecrosis of the jaw through three required elements:

Current or previous antiresorptive treatment, alone or combined with immune modulators or antiangiogenic medicines.
Exposed bone or bone probeable through an intraoral or extraoral fistula in the maxillofacial region for more than eight weeks.
No history of radiation therapy to the jaws or metastatic disease in the jaws.

Medicine exposure alone is not MRONJ. Radiographic sclerosis or trabecular changes alone also do not establish the diagnosis. Osteoradionecrosis after jaw irradiation represents a different clinical entity.

Implant placement during antiresorptive treatment

Treatment context	Implant planning	Communication
Malignant disease	Avoid elective implant placement during parenteral antiresorptive or relevant antiangiogenic therapy.	Explain the higher MRONJ risk and priority of cancer treatment.
Bisphosphonates for osteoporosis	Surgery is not automatically contraindicated. Assess duration, comorbidities, concurrent medicines, local infection and procedural extent.	Discuss the low but non-zero risk of MRONJ and early or late implant complications.
Denosumab for osteoporosis	Do not create an unsupervised delay. Any timing modification requires prescriber coordination.	Document the injection schedule and agreed plan.
Established MRONJ	Defer elective implant placement and refer for specialist management.	Separate treatment of active disease from later rehabilitation.

Poor oral hygiene, periodontal or periapical inflammation, denture trauma, smoking, diabetes, corticosteroids, chemotherapy and longer exposure can increase concern. No validated chairside score converts these variables into an individual probability.

Prevention, drug holidays and biomarkers

Prevention begins before high-risk treatment whenever medical timing permits. Comprehensive dental assessment, treatment of infection, stabilization of periodontal disease and elimination of mucosal trauma reduce the likelihood that invasive procedures will become necessary during oncology therapy.

Evidence supporting antiresorptive drug holidays remains inconclusive.
Do not delay denosumab without medical coordination because interruption may cause rebound fractures.
No bone turnover biomarker, including CTX, has a validated threshold for individual MRONJ risk.
Radiographs and CBCT support diagnosis and surgical planning but do not independently confirm MRONJ.
Follow-up should confirm mucosal closure, symptom control and continued oral maintenance.

Anticoagulants and antiplatelet medicines

Bleeding risk must be balanced against thromboembolic risk. Most outpatient dental bleeding can be controlled locally, while unnecessary treatment interruption can expose the patient to stroke, valve thrombosis, stent thrombosis or recurrent venous thromboembolism.

Medicine group	General dental principle	Qualification
Warfarin or another vitamin K antagonist	Many invasive procedures can proceed when the INR is current and within the recommended range.	SDCEP recommends treatment without interruption when INR is below 4.
Direct oral anticoagulant	Continue treatment for procedures with low bleeding risk.	For higher-risk procedures, follow current medicine-specific guidance for a missed or delayed morning dose.
Single or dual antiplatelet therapy	Treat without interruption and use local haemostasis.	Bleeding can be prolonged, but thrombotic harm from interruption can be serious.
Low molecular weight heparin	Prophylactic doses often permit treatment without interruption.	Treatment doses or uncertainty require prescriber consultation.

Plan treatment early in the day and week, limit the initial surgical field when appropriate, use packing and suturing, and discharge only after haemostasis. Provide written postoperative advice and an emergency contact pathway.

Cardiovascular disease and infective endocarditis

Elective surgery should be deferred when the patient has unstable cardiovascular symptoms, decompensated heart failure or another unresolved condition that compromises procedural safety.

The American Heart Association reserves antibiotic prophylaxis for selected patients at highest risk of an adverse outcome from infective endocarditis who undergo procedures that manipulate gingival tissue, the periapical region or oral mucosa. A murmur or valve disease does not automatically establish an indication. Oral hygiene and regular dental care remain central preventive measures.

Oncology, radiotherapy and immunosuppression

Cancer treatment can alter blood counts, mucosal integrity, immunity and healing. Implant surgery should fit the treatment phase and current clinical status.

Coordinate invasive care during active chemotherapy with the oncology team.
Use recent blood counts when the treatment may alter neutrophils or platelets and when the result will change care.
Identify the exact targeted or immune therapy because adverse effects differ by agent.
Do not independently interrupt post-transplant immunosuppression.
After head and neck radiotherapy, obtain radiation field and jaw dose information when possible.

Implants can survive in selected irradiated patients, but osteoradionecrosis and implant failure remain clinically important. The decision should account for the irradiated site, dose distribution, time since treatment, reconstructive anatomy, soft-tissue condition and oncological prognosis. No single radiation dose cutoff guarantees safety.

Corticosteroids and SSRIs

Long-term corticosteroid therapy may affect immunity, glucose control, bone metabolism and the hypothalamic-pituitary-adrenal axis. Record the exact medicine, dose, duration and indication. Do not stop treatment abruptly or improvise peri-procedural stress dosing.

Observational studies report associations between SSRI exposure and implant failure or bone outcomes. These findings do not establish causation and may be influenced by depression, smoking, comorbidity and other factors. SSRI use is not an automatic implant contraindication.

Focused medical consultation

Describe the procedure, expected bleeding, surgical extent, anaesthesia and intended date.
Identify the medicines that create concern and explain the proposed local management.
Ask whether the systemic condition is stable and whether timing fits the treatment cycle.
Request medicine modification only when guidance or clinical complexity makes it relevant.
Document the response, responsible clinician and final shared plan.

Clinical synthesis

Record the exact medicine, indication, dose, route, schedule and duration.
Separate osteoporosis dosing from cancer-related antiresorptive therapy.
Use the complete MRONJ case definition and distinguish it from osteoradionecrosis.
Avoid elective implants during high-risk oncology antiresorptive therapy.
Do not use CTX as a clearance test.
Balance bleeding control against thromboembolic harm.
Coordinate care after jaw radiotherapy and during active chemotherapy.
Never independently interrupt denosumab, anticoagulants, corticosteroids or immunosuppression.

Download the full educational material

The full PDF expands MRONJ risk stratification, antithrombotic management, oncology and radiotherapy considerations, corticosteroid exposure and focused interdisciplinary consultation.

Download the full educational material (PDF)

Selected references

Ruggiero SL, et al. AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaws – 2022 Update. J Oral Maxillofac Surg. 2022;80:920-943.
Yarom N, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37:2270-2290.
Scottish Dental Clinical Effectiveness Programme. Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs. 2nd ed. 2022.
Wilson WR, et al. Prevention of Viridans Group Streptococcal Infective Endocarditis. Circulation. 2021;143:e963-e978.
Tonea A, et al. Survival of dental implants and osteoradionecrosis in irradiated head and neck cancer patients. Clin Oral Investig. 2021;25:5579-5593.
Beuschlein F, et al. Diagnosis and Therapy of Glucocorticoid-Induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2024;109:1657-1683.

Explore related PERI-EDU resources

#UniversityEducation #OnlineCourses #ClinicalCases #PERIEDU #MRONJ #ImplantDentistry #Anticoagulants #AntiresorptiveTherapy

This material supports clinical reasoning and communication. It does not replace medicine-specific prescribing guidance, oncology planning, specialist oral surgery assessment or individualized medical care.

This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.